BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filippatos T, Tzavella E, Rizos C, Elisaf M, Liamis G. Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety 2017;16:1121-32. [DOI: 10.1080/14740338.2017.1361400] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Zhao C, Guo Y, Wang R, Cheng C, Chen X. Effect of hydrogen-rich water on the lactic acid level in metformin-treated diabetic rats under hypoxia. Korean J Physiol Pharmacol 2021;25:517-23. [PMID: 34697262 DOI: 10.4196/kjpp.2021.25.6.517] [Reference Citation Analysis]
2 Yeoh HL, Lee M, Pan WJ, Ong HY. Case of sodium-glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis. BMJ Case Rep 2021;14:e235953. [PMID: 34404640 DOI: 10.1136/bcr-2020-235953] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liamis G, Hoorn EJ, Florentin M, Milionis H. An overview of diagnosis and management of drug-induced hypomagnesemia. Pharmacol Res Perspect 2021;9:e00829. [PMID: 34278747 DOI: 10.1002/prp2.829] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Sampani E, Sarafidis P, Papagianni A. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opin Drug Saf 2020;19:673-82. [PMID: 32521174 DOI: 10.1080/14740338.2020.1764532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yi HC, Shi WS, Zhang YH, Zhu XZ, Yu Y, Wang XX, Dai Z, Lin Y. Comparison of electrolyte and glucose levels measured by a blood gas analyzer and an automated biochemistry analyzer among hospitalized patients. J Clin Lab Anal 2020;34:e23291. [PMID: 32147884 DOI: 10.1002/jcla.23291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clin Pharmacol 2019;11:133-43. [PMID: 31572020 DOI: 10.2147/CPAA.S172353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Tonneijck L, Muskiet MHA, Blijdorp CJ, Smits MM, Twisk JW, Kramer MHH, Danser AHJ, Diamant M, Joles JA, Hoorn EJ, van Raalte DH. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am J Physiol Renal Physiol 2019;316:F231-40. [PMID: 30353743 DOI: 10.1152/ajprenal.00432.2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
8 Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations. Anaesthesia 2018;73:1008-18. [DOI: 10.1111/anae.14251] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
9 Rizos CV, Filippatos TD, Elisaf MS. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2018;14:117-25. [PMID: 29241374 DOI: 10.1080/17425255.2018.1418325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Filippatos TD, Makri A, Elisaf MS, Liamis G. Hyponatremia in the elderly: challenges and solutions. Clin Interv Aging 2017;12:1957-65. [PMID: 29180859 DOI: 10.2147/CIA.S138535] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 7.4] [Reference Citation Analysis]
11 Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130:72-82. [PMID: 29039237 DOI: 10.1080/00325481.2018.1394152] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]